(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Associate Professor
Medical or Graduate Education:
Indiana University School of Medicine
University of Colorado - Internal Medicine
University of Colorado - Movement Disorders
Botulinum toxin injections
Movement disorders, fragile X-associated
Multiple system atrophy
Progressive supranuclear palsy (PSP)
Restless legs syndrome (RLS)
Genetics and movement disorders
Fragile X-associated tremor/ataxia syndrome
Clinical trials in Parkinson's disease
Exercise in movement disorders
University Neurologists Professional Building 1725 W. Harrison St. Suite 755 Chicago, IL 60612 Phone: (312) 563-2900 Fax: (312) 563-2024
View Larger Map • Driving Directions
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Intranuclear inclusions in a fragile X mosaic male. Pretto DI, Hunsaker MR, Cunningham CL, Greco CM, Hagerman RJ, Noctor SC, Hall DA, Hagerman PJ, Tassone F. Transl Neurodegener. 2013 2013 May 21 2(1):10. doi: 10.1186/2047-9158-2-10. Study in Parkinson Disease of Exercise (SPARX): Translating high-intensity exercise from animals to humans. Moore CG, Schenkman M, Kohrt WM, Delitto A, Hall DA, Corcos D. Contemp Clin Trials. 2013 2013 Jun 14 36(1):90-98. doi: 10.1016/j.cct.2013.06.002. [Epub ahead of print] Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Schenkman M, Hall DA, Barón AE, Schwartz RS, Mettler P, Kohrt WM. Phys Ther. 2012 2012 Nov 92(11):1395-410. doi: 10.2522/ptj.20110472. Epub 2012 Jul 19. Fragile X-associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Hall D, Tassone F, Klepitskaya O, Leehey M. Mov Disord. 2012 2012 Feb 27(2):296-300. doi: 10.1002/mds.24021. Epub 2011 Dec 11. Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment. Hall DA, O'keefe JA. Tremor Other Hyperkinet Mov (N Y). 2012 2012 2. doi:pii: tre-02-56-352-1. Epub 2012 May 11. Pragmatic communication is impaired in Parkinson disease. Hall D, Ouyang B, Lonnquist E, Newcombe J. Int J Neurosci. 2011 2011 May 121(5):254-6. doi: 10.3109/00207454.2010.550389. Epub 2011 Feb 25. Executive dysfunction in young FMR1 premutation carriers: forme fruste of FXTAS or new phenotype? Berry-Kravis E, Hall DA. Neurology. 2011 2011 Aug 16 77(7):612-3. doi: 10.1212/WNL.0b013e3182299f98. Epub 2011 Jul 20. No abstract available. FMR1 gray-zone alleles: association with Parkinson's disease in women? Hall DA, Berry-Kravis E, Zhang W, Tassone F, Spector E, Zerbe G, Hagerman PJ, Ouyang B, Leehey MA. Mov Disord. 2011 2011 Aug 15 26(10):1900-6. doi: 10.1002/mds.23755. Epub 2011 May 12. Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. Ortigas MC, Bourgeois JA, Schneider A, Olichney J, Nguyen DV, Cogswell JB, Hall DA, Hagerman RJ. J Clin Psychopharmacol. 2010 2010 Oct 30(5):642-4. doi: 10.1097/JCP.0b013e3181f1d10a. No abstract available. Shoulder pain in Parkinson's disease: a case-control study. Madden MB, Hall DA. Mov Disord. 2010 2010 Jun 15 25(8):1105-6. doi: 10.1002/mds.23048. No abstract available. Parkinsonism and cognitive decline in a fragile X mosaic male. Hall D, Pickler L, Riley K, Tassone F, Hagerman R. Mov Disord. 2010 2010 Jul 30 25(10):1523-4. doi: 10.1002/mds.23150. No abstract available. Tremor in 48,XXYY syndrome. Tartaglia N, Borodyanskaya M, Hall DA. Mov Disord. 2009 2009 Oct 15 24(13):2001-7. doi: 10.1002/mds.22700. Erratum in: Mov Disord. 2010 Aug 15;25(11):1764. Borodyanskya, Mariya [corrected to Borodyanskaya, Mariya]. Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Hall DA, Howard K, Hagerman R, Leehey MA. Parkinsonism Relat Disord. 2009 2009 Feb 15(2):156-9. doi: 10.1016/j.parkreldis.2008.04.037. Epub 2008 Jun 20. Movement disorders associated with aripiprazole use: a case series. Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC. Int J Neurosci. 2009 2009 119(12):2274-9. doi: 10.3109/00207450903225553. Persistent neurobehavioral signs and symptoms following West Nile fever. Hall DA, Tyler KL, Frey KL, Kozora E, Arciniegas DB. J Neuropsychiatry Clin Neurosci. 2008 Winter 20(1):122-3 Endurance exercise training to improve economy of movement of people with Parkinson disease: three case reports. Schenkman M, Hall D, Kumar R, Kohrt WM. Phys Ther. 2008 Jan 88(1):63-76 Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Grigsby J, Brega AG, Engle K, Leehey MA, Hagerman RJ, Tassone F, Hessl D, Hagerman PJ, Cogswell JB, Bennett RE, Cook K, Hall DA, Bounds LS, Paulich MJ, Reynolds A. Neuropsychology. 2008 Jan 22(1):48-60. Adult-onset Alexander disease with progressive ataxia and palatal tremor. Howard KL, Hall DA, Moon M, Agarwal P, Newman E, Brenner M. Mov Disord. 2008 Jan 23(1):118-22. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems Hagerman RJ, Hall DA, Coffey S, Leehey M, Bourgeois J, Gould J, Zhang L, Seritan A, Berry-Kravis E, Olichney J, Miller JW, Fong AL, Carpenter R, Bodine C, Gane LW, Rainin E, Hagerman H, Hagerman PJ Clin Interv Aging 2008 3(2):251-62
To watch a brief video of Deborah A. Hall, MD, PhD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
I started to volunteer when I was in junior high. I volunteered at a radiation therapy center for cancer. And once I started to get involved in that, I understood that I could bring together my love of science with the ability to help people. And now here at Rush, I’m involved in gene therapy studies for Parkinson’s disease. We believed for a long time it would be medications that would be the clue to improving patients’ quality of life. But now we have these very exciting therapies that we’re testing in the clinic. And we’re very hopeful that these will be helpful in the long run for patients.
You occasionally have a patient that comes in and says, “Doc, I’m better.” And that is probably the most rewarding thing that we can hear when we’re in the clinic.